Dr Bih Chendi Joins VALIDATE Network as Associate Member

Congratulations to Dr Bih Chendi on her successful application to join the VALIDATE Network as an Associate Member! VALIDATE is a global network of interdisciplinary researchers focused on tackling some of the world’s most challenging infectious diseases—particularly in low- and middle-income countries (LMICs). These include diseases caused by mycobacteria (like…

Dr Bih Chendi Selected for RePORT International’s Prestigious Early-Stage Investigator Fellowship

We are thrilled to announce that Dr Bih Chendi has been selected for the RePORT International Coordinating Center (TB-RICC) Early-Stage Investigator Fellowship Program under the supervision of Professor Novel Chegou, Head of ChegouLab within the Immunology Research Group at Stellenbosch University. The RePORT International initiative—Regional Prospective Observational Research for Tuberculosis—focuses…

Support rare disease patients through art

Join the Rare Disease Genomics Research Group’s online charity art auction to support rare disease patients and their families. Featuring A1 canvas prints by Cumine van Tonder, the registrar in medical genetics, these artworks blend nature and anatomy, reflecting the human body’s connection to the natural world. How to Participate:…

Rare Talent for Rare Disease concert

February is Rare Disease Month, and the Faculty of Medicine and Health Sciences is marking the occasion with a concert in the Endler Hall on 15 February at 19:00. With over 300 million people worldwide affected by rare diseases—most of them children—your support can make a real difference. Event Highlights: Performances…

Stellenbosch University Strengthens Bilateral Collaboration in the Global South for Capacity Building in Tuberculosis Genomics

Written by Dr Emilyn Costa Conceicao Brazil and South Africa share more than economic ties as members of the BRICS bloc; they also face significant public health challenges as both are included on the World Health Organization’s list of countries with high tuberculosis (TB) burdens. Investing in advanced technologies to…